Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) went up by 46.88% from its latest closing price compared to the recent 1-year high of $212.00. The company’s stock price has collected 1.41% of gains in the last five trading sessions. Barron’s reported 1 hour ago that Alnylam Stock Rockets 50% as Trial Results Raise Hope for a Blockbuster
Is It Worth Investing in Alnylam Pharmaceuticals Inc. (NASDAQ :ALNY) Right Now?
Plus, the 36-month beta value for ALNY is at 0.76. Opinions of the stock are interesting as 15 analysts out of 26 who provided ratings for Alnylam Pharmaceuticals Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 9 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $202.13, which is -$4.67 below the current price. ALNY currently public float of 119.80M and currently shorts hold a 4.16% ratio of that float. Today, the average trading volume of ALNY was 802.26K shares.
ALNY’s Market Performance
ALNY stocks went up by 1.41% for the week, with a monthly drop of -4.24% and a quarterly performance of 2.10%, while its annual performance rate touched -20.22%. The volatility ratio for the week stands at 4.50% while the volatility levels for the past 30 days are set at 3.76% for Alnylam Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 44.15% for ALNY stocks with a simple moving average of 33.19% for the last 200 days.
Analysts’ Opinion of ALNY
Many brokerage firms have already submitted their reports for ALNY stocks, with Cantor Fitzgerald repeating the rating for ALNY by listing it as a “Neutral.” The predicted price for ALNY in the upcoming period, according to Cantor Fitzgerald is $175 based on the research report published on July 13th of the current year 2022.
ALNY Trading at 49.76% from the 50-Day Moving Average
After a stumble in the market that brought ALNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.64% of loss for the given period.
Volatility was left at 3.76%, however, over the last 30 days, the volatility rate increased by 4.50%, as shares surge +39.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +58.49% upper at present.
During the last 5 trading sessions, ALNY rose by +47.66%, which changed the moving average for the period of 200-days by +0.51% in comparison to the 20-day moving average, which settled at $147.65. In addition, Alnylam Pharmaceuticals Inc. saw -16.28% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ALNY starting from Tanguler Tolga, who sale 1,754 shares at the price of $150.00 back on Jul 05. After this action, Tanguler Tolga now owns 1,754 shares of Alnylam Pharmaceuticals Inc., valued at $263,100 using the latest closing price.
PAUL STEVEN M, the Director of Alnylam Pharmaceuticals Inc., sale 15,000 shares at $170.69 during a trade that took place back on Apr 01, which means that PAUL STEVEN M is holding 1,000 shares at $2,560,371 based on the most recent closing price.
Stock Fundamentals for ALNY
Current profitability levels for the company are sitting at:
- -83.93 for the present operating margin
- +83.40 for the gross margin
The net margin for Alnylam Pharmaceuticals Inc. stands at -101.01. Equity return is now at value -204.20, with -28.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.04.